

## Special Issue

# Translational Discoveries in T-cell Lymphomas

### Message from the Guest Editors

Despite the introduction of successful novel therapeutic approaches in the treatment of human lymphomas, the survival of patients with T-cell lymphomas (TCL) is dismal. As of today, remarkable advancements have been impaired by TCL rarity and the limited knowledge of pathogenetic mechanisms, together with a lack of reliable pre-clinical models. Recent efforts have led to dramatic improvements in TCL functional and genetic stratification, leading to a fast-evolving scenario. In this new perspective, we predict that the integration of TCL phenotypic and molecular features will foster translational discoveries to be tested in new informative pre-clinical models, ultimately refining diagnosis and improving the clinical outcome of patients. This Special Issue aims to collect research articles and reviews from researchers investigating different aspects of TCL tumorigenesis, with a focus on translational discoveries accounting for new targeted agents, immunotherapies and chimeric antigen receptor (CAR)-adoptive strategies (CAR-T/CAR-NK cells).

### Guest Editors

Dr. Danilo Fiore

Department of Molecular Medicine and Medical Biotechnology,  
University of Naples Federico II, Via Tommaso De Amicis 95, Laboratori  
IEOS, CNR, Scala C, III piano, 80131 Naples, Italy

Dr. Luca Vincenzo Cappelli

Department of Pathology and Laboratory Medicine, Weill Cornell  
Medicine, New York, NY 10065, USA

### Deadline for manuscript submissions

closed (15 December 2022)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/72743](https://mdpi.com/si/72743)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).